Search the Newsreel

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, August 12, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate …

Bank of America Corp (TVTX) discloses 5.8% beneficial stake in Travere Therapeutics

Bank of America Corporation has disclosed a 5.8% beneficial ownership stake in Travere Therapeutics, Inc., amounting to 5,439,155 shares. This filing, a Schedule 13G, indicates that Bank of America and its subsidiaries hold shared voting power over 5,103,492 shares and shared dispositive power over …

What is HC Wainwright's Estimate for TVTX Q3 Earnings?

Travere Therapeutics, Inc. $TVTX Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its holdings in Travere Therapeutics (NASDAQ:TVTX) by 354.4% in the first quarter, now owning 68,317 shares valued at $2.03 million. Other institutional investors also boosted their stakes, and several analysts have raised their price targets for the stock, …

Travere Therapeutics Inc (TVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

State Street Corporation (TVTX) discloses 4.6% beneficial stake in Travere

State Street Corporation reported a 4.6% beneficial ownership stake in Travere Therapeutics, Inc. common stock, totaling 4,256,224 shares as of June 30, 2026. This Schedule 13G filing indicates that State Street, through its investment management subsidiaries, holds these shares with shared voting and dispositive …

Travere Therapeutics (TVTX) Gets A Fresh Valuation Test As FILSPARI Fuels Q2 Revenue

Why Travere Therapeutics (TVTX) Is Up 9.0% After FILSPARI-Driven Q2 Revenue Jump And Wider Loss

Travere Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TVTX) 2026-08-06

This article provides the slide deck published by Travere Therapeutics, Inc. for their 2026 Q2 earnings call. The company reported an EPS of -$0.10, missing estimates by $0.42, but revenue of $169.58M, beating by $12.32M and showing a 48.17% year-over-year increase. The earnings call …

FMR LLC (TVTX) discloses 7.1M Travere Therapeutics shares under amended 13G

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing their beneficial ownership of 7,142,482.22 shares of Travere Therapeutics Inc. (TVTX) common stock, which represents a 7.7% stake. FMR LLC holds sole voting power over 6,173,667.45 shares and sole dispositive power …

Travere Therapeutics (TVTX) Stock Climbs On FILSPARI Momentum As Losses Deepen

Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again) (NASDAQ:TVTX)

Does FILSPARI-Driven Revenue Growth And Wider Losses Change The Bull Case For Travere Therapeutics (TVTX)?

Travere Therapeutics Reports Second Quarter 2026 Financial Results

Travere Therapeutics (Nasdaq: TVTX) reported strong second-quarter 2026 financial results, driven by robust demand for FILSPARI, with U.S. net product sales growing 96% year-over-year to $141 million. The company announced the successful launch of FILSPARI in FSGS and continued growth in IgA nephropathy, alongside …

Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $65.71, Implies 17% Upside

Analysts have raised the average 12-month price target for Travere Therapeutics, Inc. (TVTX) stock to $68.36, up from $59.14. This new target suggests a potential upside of approximately 22% from the August 4th closing price. The consensus rating from 15 analysts remains a "Buy," …

Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ...

Travere Therapeutics reported strong Q2 2026 results, driven by record demand for FILSPARI, particularly with its successful launch in FSGS, exceeding initial expectations. The company also strengthened its balance sheet and expanded its rare kidney disease portfolio through a new licensing agreement, despite facing …

TRAVERE THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $64 FROM $54

Jefferies has raised its target price for Travere Therapeutics, Inc. (TVTX.O) to $64 from the previous $54. This indicates a more optimistic outlook by the firm on the pharmaceutical company's future performance. The report was published by Reuters on August 5, 2026.

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Earnings call transcript: Travere Therapeutics jumps on q2 2026 sales beat

Travere Therapeutics reported Q2 2026 revenue of $169.6 million, exceeding analyst forecasts, driven by strong sales of its kidney drug FILSPARI. The drug's sales rose 96% year-over-year to $141.1 million, benefiting from accelerated demand in both IgA nephropathy and the newly launched FSGS indication. …

Travere Therapeutics (NASDAQ:TVTX) Issues Quarterly Earnings Results

Travere Therapeutics Q2 Swings to Adjusted Loss, Revenue Rises

Travere Therapeutics reported an adjusted loss in Q2 compared to a profit last year, despite an increase in revenue. The company's adjusted net loss was $0.34 per share, while total revenue grew to $65.4 million from $51.7 million in the prior year quarter. The …

Travere Therapeutics (TVTX) Releases Q2 2026 Earnings: Revenue Growth but Net Loss Narrows

Travere Therapeutics (NASDAQ: TVTX) grows FILSPARI sales and issues $525M converts

Earnings Flash (TVTX) Travere Therapeutics, Inc. Reports Q2 Revenue $169.6M, vs. FactSet Est of $157.3M

Travere Therapeutics, Inc. (TVTX) announced its Q2 revenue of $169.6 million, exceeding FactSet's estimate of $157.3 million. This financial update indicates a stronger-than-anticipated performance for the biopharmaceutical company during the second quarter of 2026. The company specializes in therapies for rare kidney and metabolic …

Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say

Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Liquidity Mapping Around (TVTX) Price Events

This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) focusing on liquidity mapping and price events. It highlights weak near-term sentiment challenging long-term strength, an exceptional risk-reward short setup, and divergent sentiment across different time horizons. The report also provides three distinct AI-generated trading strategies …

Travere Therapeutics Market Sentiment

This article analyzes market sentiment for Travere Therapeutics (TVTX) by examining analyst consensus, short interest, options flow, and insider activity. Analysts show a "Buy" consensus with an average price target of $44, while short interest is declining, and options flow indicates bullish sentiment with …

Travere Therapeutics Number of Employees 2026 | Employee Count & Headcount Data

Travere Therapeutics (NASDAQ: TVTX) had 496 employees worldwide as of March 2026, marking a 4.6% growth since 2023. The company is actively hiring, although job postings have declined by 90.2% in 2026. The average employee salary is $211,323, and overall employee sentiment is negative …

Travere Therapeutics faces earnings test on Filspari FSGS launch By Investing.com

Travere Therapeutics Inc. is approaching its second-quarter earnings report, where investors will closely monitor the performance of its newly FDA-approved kidney drug, Filspari, for focal segmental glomerulosclerosis (FSGS). Analysts anticipate a loss of 8 cents per share on revenue of $160.7 million, with a …

Travere Therapeutics (TVTX) to Release Earnings on Wednesday

Travere Therapeutics, Inc. Revenue Breakdown – NASDAQ:TVTX

Travere Therapeutics, Inc. (NASDAQ: TVTX) generated a total revenue of $490.73 million USD last year. The FILSPARI segment was the primary revenue driver, contributing $322.00 million USD, a significant increase from the previous year. The company's largest market contribution came from the United States, …

Travere Therapeutics Q2 Results: Earnings Date Set for August 4

Travere Therapeutics, Inc. (NASDAQ: TVTX) is set to release its second quarter 2026 financial results on August 4, 2026, after the U.S. markets close. Following the release, a conference call and webcast will be held at 4:30 p.m. ET to discuss the results and …